Search
resmetirom (Rezdiffra)
Indications:
- treatment of nonalcoholic steatohepatitis (NASH) with fibrosis [1]
Dosage:
- 80 mg or 100 mg PO QD
Adverse effects:
- diarrhea, nausea
Mechanism of action:
- liver-directed, thyroid hormone receptor beta agonist
- reduces hepatic fibrosis in patients with NASH
- 14-16% reduction in LDL cholesterol
General
gastrointestinal agent
Database Correlations
PUBCHEM cid=15981237
References
- Bassett M
Resmetirom Poised to Become First NASH Treatment.
Phase III study demonstrated drug is effective in resolving NASH and improving
liver fibrosis.
MedPage Today February 7, 2024
https://www.medpagetoday.com/gastroenterology/generalhepatology/108629
- FDA News Release
U.S. Food and Drug Administration.FDA approves first treatment for patients with
liver scarring due to fatty liver disease.
FDA 2024 Mar 14;
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
- Harrison SA, Bedossa P, Guy CD et al
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med 2024; 390:497-509. Feb 8
PMID: 38324483
https://www.nejm.org/doi/full/10.1056/NEJMoa2309000
- Cusi K.
Selective agonists of thyroid hormone receptor beta for the treatment of NASH.
N Engl J Med 2024 Feb 8; 390:559
PMID: 38324491
https://www.nejm.org/doi/10.1056/NEJMe2314365